After stealing the show last year, biotech ETFs have again emerged as star performers this year. Biotech products have not only outperformed the broader equity markets but have been the best performing products in the U.S. market since the start of... (full story)
The US Supreme Court will begin hearing one of the most important cases related to healthcare starting today. King v. Burwell is the biggest challenge Obamacare has had to deal with till now and threatens to derail President Obama's signature... (full story)
John Bogle made headlines a few weeks back when he declared that a US investor shouldn't have any foreign exposure. He was making a fairly active allocation decision here by saying that an investor should maintain a strict home bias. I said this... (full story)
IndexIQ CEO Adam Patti joined ETF Trends Publisher Tom Lydon at the ETF.com Inside ETFs conference in Hollywood, Fla. to discuss the firm’s lineup of alternative ETFs as well as IndexIQ’s partnership with New York Life that comes with that firm’s... (full story)
The education of any business person is incomplete if it doesn't include a thorough reading of Warren Buffett's annual letters to shareholders. I often say that I have learned more from reading his annual letters than I have reading anything else.... (full story)
Few, if any, investment factors have received acclaim and attention afforded to the value factor. Along with the quality factor, value is the factor most frequently employed in factor-based exchange traded funds. It is easy to understand the allure... (full story)
Healthcare exchange traded funds were up to their old tricks again Wednesday when nine such ETFs made all-time highs. That is nine healthcare ETFs making all-time highs on a day in which U.S. stocks sank.
That is nine of 14 ETFs overall that... (full story)